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ABSTRACT
Objective The aim of the current study was to 
evaluate the 2- year cost- utility ratio between tapering 
conventional synthetic disease- modifying antirheumatic 
drugs (csDMARD) first followed by the tumour necrosis 
factor (TNF)- inhibitor, or vice versa, in patients with 
rheumatoid arthritis (RA).
Methods Two- year data of the Tapering strategies in 
Rheumatoid Arthritis trial were used. Patients with RA, 
who used both a csDMARD and a TNF- inhibitor and had 
a well- controlled disease (disease activity score ≤2.4 
and swollen joint count≤1) for at least 3 months, were 
randomised into gradual tapering the csDMARD first 
followed by the TNF- inhibitor, or vice versa. Quality- 
adjusted life years (QALYs) were derived from the 
European Quality of life questionnaire with 5 dimensions. 
Healthcare and productivity costs were calculated with 
data from patient records and questionnaires. The 
incremental cost- effectiveness ratio and the incremental 
net monetary benefit were used to assess cost 
effectiveness between both tapering strategies.
Results 94 patients started tapering their TNF- inhibitor 
first, while the other 95 tapered their csDMARD first. 
QALYs (SD) were, respectively, 1.64 (0.22) and 1.65 
(0.22). Medication costs were significantly lower in 
the patients who tapered the TNF- inhibitor first, while 
indirect cost were higher due to more productivity loss 
(p=0.10). Therefore, total costs (SD) were €38 833 
(€39 616) for tapering csDMARDs first, and €39 442 
(€47 271) for tapering the TNF- inhibitor (p=0.88). For 
willingness- to- pay (WTP) levels <€83 800 tapering, the 
csDMARD first has the highest probability of being cost 
effective, while for WTP levels >€83 800 tapering the 
TNF- inhibitor first has the highest probability.
Conclusion Our economic evaluation shows that costs 
are similar for both tapering strategies. Regardless of the 
WTP, tapering either the TNF- inhibitor or the csDMARD 
first is equally cost effective.
Trial registration number NTR2754.
INTRODUCTION
The optimal management for rheumatoid arthritis 
(RA) comprises an early, intensive and treat- to- 
target management approach, which has the highest 
chance of inducing remission and preventing joint 
damage.1 2 In case of sustained remission, tapering 
of treatment can be considered to reduce side- effects 
and save costs.3 In the Netherlands, more than 
€300 million are spent on the use of biological 
therapy for rheumatic diseases.4 On the other hand, 
treatment with conventional synthetic disease- 
modifying antirheumatic drugs (csDMARDs) gener-
ally costs only one- tenth of the cost of a biological.5 
Although rheumatologists carefully consider initia-
tion of biologicals, uniform tapering decisions are 
lacking, and therefore biological tapering is not 
always directly performed when sustained remis-
sion is achieved.6 Tapering of biologicals could 
reduce healthcare costs.
In the Tapering strategies in Rheumatoid Arthritis 
(TARA) trial, two tapering strategies were compared, 
namely tapering the tumour necrosis factor (TNF)- 
inhibitor first followed by the csDMARD, or vice 
versa. Within the first year, in which either the 
TNF- inhibitor or the csDMARD was gradually 
tapered within 6 months, there were no significant 
Key messages
What is already known about this subject?
 ► Savings on healthcare and societal costs could 
be obtained by tapering quickly and possibly 
stopping medication when patients with 
rheumatoid arthritis reach sustained remission.
 ► Current European League Against Rheumatism 
guidelines recommend to taper medication 
when patients with rheumatoid arthritis are in 
sustained remission; however, evidence for an 
optimal tapering approach is currently sparse.
What does this study add?
 ► The Tapering strategies in Rheumatoid Arthritis 
trial is the first randomised controlled trial 
which included a cost- utility analysis on two 
active, gradual tapering strategies.
How might this impact on clinical practice or 
future developments?
 ► Both tapering strategies are cost effective 
and depending on the viewpoint (payer’s or 
societal perspective) and willingness- to- pay 
threshold, the tumour necrosis factor- inhibitor 
or conventional synthetic disease- modifying 
anti- rheumatic drugs can be tapered first.
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differences in flare rates, disease activity, functional ability and 
quality of life, although we did observe numerical differences 
(10% in flare rates), and less patients in clinical remission.7 From 
a clinical viewpoint, one could argue that the order of tapering 
is not relevant. On the other hand, TNF- inhibitors are far more 
expensive than csDMARDs; therefore, from a health economics 
perspective, it is more sensible to taper the TNF- inhibitor first. 
Previous studies already showed that tapering biologicals leads 
to a reduction of medication and medical consumption costs, 
also known as direct costs, but could also result in a decrease 
in quality of life.8–11 Tapering of medication might lead to an 
increase in disease activity and consequently to a disease flare. 
This could lead to more pain and disability, possibly resulting 
in more productivity loss and sick leave. However, not much 
is known about aforementioned possible effects. Furthermore, 
none of the aforementioned studies compared two active 
tapering strategies.11 12
Moreover, a previous study already showed that disease flares 
have a significant impact on patients’ lives, which among other 
things could lead to productivity loss.13 As mentioned earlier, the 
effect of a flare on societal costs is not known. Nor do we know 
whether the healthcare (direct) cost reduction due to tapering 
treatment outweigh the possible increase in productivity (indi-
rect) costs.
Therefore, our aim is to investigate which gradual tapering 
strategy has the best cost- utility ratio over a period of 2 years. 
Furthermore, we want to explore the effect of tapering on both 
medical and societal costs.
PATIENTS AND METHODS
Patients
For this study, data were used from the TARA trial (NTR2754). 
TARA, a multicentre, single- blinded trial was carried out in 12 
rheumatology centres in the Netherlands between September 
2011 and July 2016. All patients gave written informed consent 
before inclusion.
Primary aims of the TARA study were to assess effectiveness 
and cost effectiveness of two tapering strategies, from a societal 
perspective. An extended description of the TARA study and 
clinical effectiveness outcomes can be found elsewhere.7 14 Inclu-
sion criteria for the TARA trial were: adult patients with RA, 
with a well- controlled disease, defined as a disease activity score 
(DAS44) ≤2.4 and a swollen joint count (SJC) ≤1 at two consec-
utive time points within a 3- month interval, who were using a 
combination of a csDMARD and a TNF- inhibitor.
Randomisation and masking
Patients were randomised using minimisation randomisation 
stratified for centre into tapering the csDMARD in the first 
year followed by tapering the TNF- inhibitor in the second year, 
or vice versa. No other factors were used for the minimisation 
randomisation. Trained research nurses, blinded to the allocated 
treatment arm throughout the study, examined the patients.
Design
The csDMARD and TNF- inhibitor were both gradually tapered 
in three steps. csDMARD tapering was realised by cutting the 
dosage into half, a quarter and thereafter it was stopped. The 
TNF- inhibitor was tapered by doubling the interval between 
gifts, followed by cutting the dosage into half, and thereafter it 
was stopped. If patients remained flare free, the first drug was 
completely tapered after 6 months.
Both tapering strategies had a treat- to- target approach with 
3 monthly visits. At each visit, patients were assessed whether 
they maintained low disease activity (DAS≤2.4) while tapering 
their medication. If a disease flare occurred, defined as a 
DAS>2.4 and/or SJC>1, tapering was stopped and the last 
effective treatment, when the patient still had well- controlled 
disease, was restarted. No further attempts were taken to taper 
medication. Treatment was intensified at each visit until low 
disease activity was reached again.
Concurrent treatment with non- steroidal anti- inflammatory 
drugs and intra- articular glucocorticoid injections was allowed. 
In case of a flare, one intra- muscular glucocorticoid injection was 
allowed to be given as bridging therapy, in addition to switching 
to the last effective dosage of the csDMARD or TNF- inhibitor.
Effectiveness and cost assessment
The primary outcome of the TARA study was the number of 
disease flares. For the cost effectiveness, the main outcome was 
the incremental cost- effectiveness ratio (ICER). The ICER is the 
ratio of the difference in costs compared with the difference 
in quality- adjusted life years (QALYs) between both tapering 
strategies. Costs per QALY were calculated, since coverage of 
prescribed drugs by Dutch health insurance companies depends 
on this outcome. The required threshold per additional QALY 
gained to be funded for a new intervention in the Netherlands 
is €50 000.15–17 QALYs express the impact of the disease on 
patients’ health over time. Living in perfect health for 1 year 
corresponds to 1 QALY, living in perfect health for 2 years corre-
sponds to 2 QALYs. Zero QALYs reflects death at baseline.18 
QALYs were determined by calculating the area under the curve 
of the EuroQol questionnaire with 5 dimensions (EQ- 5D) with 
three levels over a 2- year period.19
Total costs are divided into healthcare (direct) and produc-
tivity (indirect) costs. We analysed healthcare and productivity 
costs from a societal perspective. Healthcare costs are the costs 
of treatment and medical consumption, whereas productivity 
costs are costs due to presenteeism, that is, working while sick, 
and absenteeism, that is, sick leave and unemployment.20
Medication costs were calculated from doses reported in the 
patients’ case records, valued according to the Dutch college of 
health insurances (online supplementary table S1).5 Duration 
of hospitalisations and admission diagnosis was recorded every 
3 months with the iMTA medical consumption questionnaire. 
Medical consumption, including hospital admissions, was valued 
at Dutch standard prices, except for costs of complementary and 
complementary medicine, which were based on American data, 
because no Dutch data are available (online supplementary table 
S2).21 22
Productivity costs included absenteeism, such as sick leave 
and reduction in work time, and presenteeism, including 
working while sick. Every 3 months, patients filled out the 
iMTA productivity cost questionnaires.23 The friction cost 
method was used to calculate the productivity costs, which 
assumes replaceability of every employee in time.19 The fric-
tion cost period is the time between the start of long- term sick 
leave, and filling the position again. Costs due to sick leave are 
solely counted during this period, which encompasses 85 days 
in the Netherlands.24 Productivity losses were valued at age- 
dependent and sex- dependent standard hourly costs (online 
supplementary table S3).25 26 All prices were obtained for the 
year 2019. Costs were not discounted, because of only 2 years 
of follow- up.
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Willingness to pay
To help decide which tapering strategy has the highest chance 
of being cost effective, two indicators were used. First, the 
cost- effectiveness acceptability curves (CEAC) were derived to 
show the probability of each tapering strategy being cost effec-
tive at different levels of willingness- to- pay (WTP) thresholds 
in comparison with each other.27 Second, the incremental net 
monetary benefit (iNMB) was used to express the incremental 
value of the tapering strategies in monetary terms at different 
levels of WTP per QALY. This results in an alternate measure 
which reports on cost- effectiveness without using the ICER. The 
iNMB was calculated as the incremental benefit times different 
levels of WTP, minus the incremental costs. A positive iNMB 
indicates that the tapering the TNF- inhibitor first is cost effec-
tive compared with tapering the csDMARD first.27
Statistical analysis
The cost- effectiveness analysis follows a superiority design. 
Sample size calculation was based on the number of disease 
flares after 1 year, which was described previously.7 All analysis 
were performed following an intention- to- treat approach.
After 2 years of follow- up, 13/94 (13.8%) in the tapering the 
csDMARD first group had dropped out, versus 9/95 (9.5%) in 
the tapering the TNF- inhibitor first group. Furthermore, 7.6% 
of patients who completed the trial did not completely fill out 
the questionnaires. Multiple imputations with chained equa-
tions, with 40 imputations, were used to handle missing data in 
baseline variables as well as in the follow- up data.28 An imputa-
tion regression model was constructed to impute EQ- 5D, unem-
ployment, loss of productivity due to sick leave (absenteeism) 
and not fully functioning (presenteeism) and the (decrease in) 
number of working hours.
For EQ- 5D, presenteeism and the amount of working hours, 
linear regression was used. The percentages of missingness for 
these variables were, respectively, 14.9%, 6.7% and 18.6%. 
For presenteeism, we log transformed the variable and used 
linear regression to impute values. For unemployment (13.6% 
missing values), we used logistic regression, and for sick leave 
(7.9% missing values) we used a Poisson regression model. The 
choice of imputation models was based on the distribution of 
the individual variables. In the regression models, we used age, 
gender, baseline values and the tapering strategy as indepen-
dent variables. Differences between imputed data, created with 
aforementioned models, and complete cases were minimal and 
showed that our imputation models are reliable (online supple-
mental table S4).
The main outcome was the ICER. A probabilistic sensitivity 
analysis for the estimation of the ICER was performed by boot-
strapping with 1000 iterations using a Monte Carlo simulation. 
Results were plotted in a cost- effectiveness plane and were used 
to estimate the 95% CI of the ICER.
Differences in outcomes between groups were analysed with 
linear regression models, and to account for stratified randomis-
ation by centre, intercepts for each centre were included.
All data were analysed using STATA V.15, using a value of 
p≤0.05 as the level of statistical significance.
RESULTS
Patients
A total of 189 patients were randomly assigned to taper the 
csDMARD (n=94) or TNF- inhibitor (n=95) first. Over 2 years, 
22 patients (11.6%) withdrew from the study, resulting in 167 
patients with a complete follow- up. At baseline, patients had an 
average symptom duration of 6.8 years and were predominantly 
women (66.1%) with an average age of 56.6 years (table 1). 
The majority of patients (55%) used etanercept as their TNF- 
inhibitor. At baseline, 47 (25%) of patients were aged above 65, 
which was the average age of retirement in the Netherlands in 
2018.29 Of the 142 patients under 65, 99 patients (70%) had 
paid work at baseline (table 1).
Healthcare costs
Mean healthcare costs (SD) were €22 484 (€8069) for tapering 
the csDMARD first and €13 616 (€9162) for tapering the TNF- 
inhibitor first (p<0.001; table 2). Respectively, 86% and 71% 
of healthcare costs were medication costs. The faster savings 
due to less TNF- inhibitor use within the group that tapered 
the TNF- inhibitor first was the main driver of the difference in 
direct costs. Within the group who tapered the csDMARDs first, 
81 (86%) were using full- dose TNF- inhibitor after 12 months, 
and 32 (34%) patients after 24 months. In the TNF- inhibitor 
tapering first group, this was 16 (17%) after 12 months, and 25 
(26%) after 24 months.
Productivity costs
Average productivity costs (SD) for tapering csDMARDs first 
and TNF- inhibitor first were, respectively, €16 349 (€38 277) 
and €25 826 (€46 289; p=0.10; tables 3 and 4). Within the 








  Age (years), mean (SD) 55.9 (14) 57.2 (11)
  Aged above 65, n (%) 22 (23) 25 (26)
  Gender, female, n (%) 67 (71) 58 (61)
Quality of life
  EQ- 5D index, mean (SD) 0.86 (0.12) 0.87 (0.11)
Disease characteristics
  Symptom duration (years), median 
(IQR)
6.0 (4.3–8.5) 6.3 (4.1–8.9)
  RF positive, n (%) 49 (57) 56 (64)
  ACPA positive, n (%) 61 (72) 65 (75)
  DAS, mean (SD) 1.1 (0.6) 1.0 (0.5)
Use of csDMARDs *
  MTX, n (%) 89 (95) 84 (88)
  SASP, n (%) 10 (11) 12 (13)
  HCQ, n (%) 24 (26) 37 (39)
  Leflunomide, n (%) 2 (2) 4 (4)
Use of TNF- inhibitors
  Etanercept, n (%) 52 (55) 52 (55)
  Adalimumab, n (%) 36 (39) 40 (43)
  Other, n (%) † 6 (7) 3 (3)
Worker- related outcomes
  Paid work, n (%) ‡ 47 (61) 52 (68)
  Working hours per week, mean (SD) 28 (8) 29 (11)
*Some patients used a combination of conventional synthetic disease modifying 
antirheumatic drugs (csDMARDs).
†Certolizumab or golimumab.
‡Number of patients with paid work and aged under 65.
ACPA, anticitrullinated protein antibody; DAS, disease activity score based on 44 
joints; EQ- 5D, European Quality of life questionnaire with 5 dimensions; HCQ, 
hydroxychloroquine; MTX, methotrexate; RF, rheumatoid factor; SASP, salazopyrine; ; 
TNF, tumour necrosis factor.
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2 years of follow- up, 20 (43%) patients with paid work called in 
sick with an average duration of 9 days in the initial csDMARD 
tapering group versus 26 patients (50%) with an average dura-
tion of 12 days within the initial TNF- inhibitor tapering group. 
Of those patients, respectively, 2 and 1 had long- term sickness 
(>3 months). Two patients who tapered the csDMARD first 
became unemployed, versus six in the group who tapered the 
TNF- inhibitor first. The working population had an average 
workweek of 32 hours after 24 months of follow- up. A decrease 
in working hours was seen in 8 and 11 patients in, respectively, 
the csDMARD and TNF- inhibitor tapering first group. Their 
average workweek decreased with 15 hours in the csDMARD 
tapering first group and 19 hours in the TNF- inhibitor tapering 
first group. Within the working population, 34 patients in the 
Table 2 Healthcare costs over 2 years of follow- up in the Tapering strategies in Rheumatoid Arthritis study according to intention to treat
Tapering csDMARDs first (n=94) Tapering TNF- inhibitor first (n=95)
Number of visits, mean (SD) Mean costs (SD) Number of visits, mean (SD) Mean costs (SD)
Medication*
  csDMARDs* €436 (€87) €972 (€123)
  TNF- inhibitor* €19 417 (€738) €9673 (€863)
  Prednisone €2.46 (€0.54) €2.84 (€0.59)
Medical consumption
  Hospitalisation 13 ‡ €326 (€1313) 15 ‡ €558 (€2271)
Standard healthcare
  Primary care physician 7.7 (9) €260 (€302) 8.9 (9) €303 (€318)
  Specialist 12.0 (6) €1153 (€647) 12 (6) €1203 (€738)
  Psychologist 0.5 (2) €18 (€83) 1.2 (8) €40 (€266)
Paramedical care
  Physical therapy 14.4 (32) €506 (€1110) 15.9 (31) €554 (€1063)
  Dietitian 0.46 (2) €14 (€62) 0.040 (0.3) €1.31 (€8.95)
  Social worker 0.14 (0.6) €9.40 (€41) 0.20 (0.8) €14 (€52)
  Speech therapist 0.04 (0.3) €1.32 (€10) 0.02 (0.2) €0.65 (€6.36)
Complementary medicine
  Homeopathy 0.83 (3) €26 (€97) 0.44 (2) €14 (€67)
Total healthcare costs, mean (SD) €22 484 (€8069) €13 616 (€9162)
*p<0.001 (linear regression adjusted for stratified randomisation).
†Number reflects the number of patients who got hospitalised within the 2 years of follow- up.
csDMARDs, conventional synthetic disease modifying antirheumatic drugs; ; TNF, tumour necrosis factor.









  Became unemployed, n (%) 2 (4) 6 (11)
Sick leave (during 2- year follow- up)
  Occurrence, n (%) 20 (21) 26 (27)
  Long- term sickness, n (%) 2 (2) 1 (1)
  Days absent, mean (SD)* 9.0 (23) 12.3 (22)
Contract hours†
  Working hours per week after 2 years, 
mean (SD)
32 (8.9) 33 (12)
  Reduction of working hours per week, 
n (%)
8 (8) 11 (11)
  Amount of reduction, hours, mean 
(SD)‡
15 (11) 19 (17)
Presenteeism
Number of patients, n (%) 34 (36) 41 (43)
  Number of days per month, mean 
(SD)§
5.3 (0.9) 6.1 (1.1)
  Average productivity loss, proportion 
(SD)¶
27.9% (13%) 26.4% (15%)
*Only indicated when patients reported sick leave.
†Only indicated when patients had paid work.
‡Only indicated for those with a reduction in working hours.
§Average productivity score was only obtained for patients indicating that they had 
loss of productivity.
¶Productivity loss was indicated only for the days with productivity loss for those 
who reported to suffer from loss of productivity.
csDMARDs, conventional synthetic disease modifying antirheumatic drugs; TNF, 
tumour necrosis factor.
Table 4 Total costs and quality- adjusted life years (QALYs) over the 





Total costs €38 833 (€39 616) €39 442 (€47 271)
Total healthcare costs* €22 484 (€8069) €13 616 (€9162)
  Medication* €19 858 (€7343) €10 648 (€8642)
  Medical consumption €2297 (€1684) €2393 (€1775)
  Hospitalisation €330 (€1319) €575 (€2305)
Total productivity costs €16 349 (€38 277) €25 826 (€46 289)
  Absenteeism €17 581 (€39 576) €23 577 (€45 382)
  Presenteeism €3290 (€9952) €4777 (€14 620)
QALYs (EQ- 5D, AUC), mean (SD) 1.64 (0.22) 1.65 (0.22)
All values are indicated as mean (SD).
*p<0.0001 (linear regression adjusted for stratified randomisation).
AUC, area under the curve; csDMARDs, conventional synthetic disease- modifying 
antirheumatic drugs; EQ- 5D, EuroQol questionnaire with 5 dimensions; ; TNF, 
tumour necrosis factor.
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csDMARD tapering first group and 41 patients in the TNF- 
inhibitor tapering first group indicated that they had days on 
which they were less productive. On average, this were 5 and 6 
days per month, with a mean productivity loss on these days of 
28% and 26%, respectively (table 3). Subanalyses of men and 
women did not result in differences in productivity costs (data 
not shown).
Cost-effectiveness analysis
The mean EQ- 5D index (SD) after 24 months of follow- up was 
0.81 (0.13) for tapering the csDMARD first, and 0.83 (0.16) 
for tapering the TNF- inhibitor first. Average QALYs (SD) over 
2 years for tapering csDMARDs first or TNF- inhibitor first were, 
respectively, 1.64 (0.22) and 1.65 (0.22; table 4). Total costs 
(SD) were €38 833 (€39 616) for tapering csDMARDs first, and 
€39 442 (€47 271) for tapering the TNF- inhibitor (p=0.88; 
table 4).
The ICER (95% CI) between tapering csDMARDs first minus 
the TNF- inhibitor first was €60 919 per QALY (−€90 638 per 
QALY to €212 475 per QALY), indicating that tapering TNF- 
inhibitor first was on average €60 919 less expensive per QALY 
compared with tapering the csDMARD first. However, the CI 
is very wide due to a minimal difference in QALYs and costs 
between the two tapering strategies. To illustrate this, the anal-
ysis of uncertainty in the estimation of the ICER was visualised 
with the cost- effectiveness planes for the two tapering strategies 
compared with each other (figure 1A). The iNMB was €1134 
(95% CI €761 to €1507) in favour of tapering TNF- inhibitor first 
for a WTP level of €50 000, which is the current level of WTP 
in the Netherlands for treatment of RA (online supplemental 
figure S1).15–17 Our CEAC shows similar results (figure 1B). 
For WTP levels <€83 800 tapering, the csDMARD first has the 
highest probability of being cost effective, while for WTP levels 
>€83 800 tapering the TNF- inhibitor first has the highest prob-
ability. In between WTP levels of €53 800 and €83 800, both 
strategies were evenly cost effective (probability 50%). This indi-
cates that depending on the WTP threshold either tapering the 
TNF- inhibitor or csDMARD first is more cost effective. More-
over, the CEAC shows that both lines are almost horizontal after 
the crossing and that the difference is small, which is due to the 
small differences in QALYs and costs.
DISCUSSION
In this study, we showed that healthcare costs were significantly 
lower in patients who tapered the TNF- inhibitor first, but 
productivity costs in this group were higher due to more absen-
teeism and presenteeism compared with the patients who tapered 
the csDMARD first. The ICER (95% CI) between tapering 
csDMARDs first minus the TNF- inhibitor first was €60 919 per 
QALY (−€90 638 to €212 475). Total costs (SD) were €38 833 
(€39 616) for tapering csDMARDs first, and €39 442 (€47 271) 
for tapering the TNF- inhibitor first (p=0.88). Depending on the 
WTP threshold either tapering the TNF- inhibitor or csDMARD 
first has the highest probability of being cost effective.
Previous studies showed that savings on healthcare and soci-
etal costs could be obtained by treating to target within newly 
diagnosed patients with RA.30 More savings could be obtained 
by tapering quickly, and possibly stopping the medication when 
patients with RA reach sustained remission. Currently, several 
trials have reported on the feasibility of tapering; however, cost- 
effectiveness analyses are scarce. A systematic review on tapering 
and stopping treatment in patients with RA reported that only 
2 out of 14 included studies performed a cost- effectiveness 
analysis, although costs are nowadays an important reason 
why tapering or stopping treatment is considered by treating 
rheumatologists.31
Previous studies reported on the cost effectiveness of tapering 
or stopping medication versus a continuation group. The Dose 
REduction Strategy of Subcutaneous TNF inhibitors (DRESS) 
study for example showed a significant cost- saving after tapering 
of adalimumab or etanercept, without a clinically meaningful 
loss in QALYs.12 The Spacing ofTNF- blocker injections in Rheu-
matoid ArthritiS Study (STRASS) also reported on cost effec-
tiveness. Within this trial, the interval between TNF- inhibitor 
injections was extended and compared with a control group 
that continued their medication. Healthcare costs were signifi-
cantly lower in the tapering group, but this was accompanied 
with a significant loss in QALYs.11 Although both studies also 
Figure 1 Summary of economic evaluation of tapering conventional synthetic disease- modifying antirheumatic drugs (csDMARDs) first minus 
tapering tumour necrosis factor (TNF)- inhibitor first. (A) Results of 1000 bootstrapped replications, presented in a cost- effectiveness plane which 
represents uncertainty of the cost- effectiveness ratio. (B) Cost- effectiveness acceptability curve for tapering csDMARDs first versus tapering TNF- 
inhibitor first. Results of 1000 bootstrapped replication, presented for several levels of willingness to pay (WTP), indicated per quality- adjusted life 
year (QALY).
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reported on productivity costs, they did not take presenteeism 
into account. In our study, the QALYs did not differ between 
both tapering strategies and were comparable to the QALYs of 
the control groups in previous mentioned trials (DRESS 1.67 
and STRASS 1.68).11 12
The strengths of the current study include the randomised 
design. Although originally the TARA trial was powered to find a 
20% difference in disease flares, cost effectiveness was a parallel 
primary outcome. Also, validated outcome measures were used 
for the QALY calculation. Furthermore, we used real data to 
calculate healthcare and productivity costs, instead of using a 
model. Moreover, for calculating productivity costs, we included 
absenteeism as well as presenteeism, thereby taking into account 
all costs due to productivity loss. Finally, the TARA trial is the 
first randomised controlled trial reporting on the cost utility 
between two gradual tapering strategies.
Some limitations should also be noted. First of all, the targeted 
sample size was not reached. This was due to difficulties with 
inclusion, and the start of another trial using the same pool 
of eligible patients. For the primary outcome (disease flares), 
we performed a sensitivity analysis, which showed similar 
outcomes.7 Furthermore, the follow- up duration was only 2 
years. Ideally, long- term effects of tapering and stopping treat-
ment should be taken into account as well. In our current design, 
patients completely tapered their medication after 18 months, 
if no flare occurred. This means that we only have 6 months 
of follow- up when patients are in DMARD- free remission. Late 
flares were, therefore, not considered in our study and might 
change current outcomes by an increase in healthcare costs on 
the long term, but might also influence productivity costs and 
quality of life.
Generalisability of the current study might be difficult, since 
every country has its own social security and healthcare system. 
Also, treatment prices differ. Costs of labour vary between coun-
tries, and more importantly, rules and regulations for social secu-
rity regulation differ across countries. The possibility to stay at 
home when not feeling well is very different across countries 
within Europe.32 In the Netherlands, people can call in sick 
without consulting a doctor, while this is obligatory in some 
other countries. This could cause a shift between presenteeism 
and absenteeism when comparing the Netherlands to other 
countries. Fortunately, in our current analysis, we do take into 
account both. Since we found that the group that tapered the 
TNF- inhibitor first encountered more costs due to both presen-
teeism and absenteeism (table 3, p=0.39 and p=0.20, respec-
tively), we believe that our indirect costs are generalisable to all 
countries.
In the current study, we found a significant difference in 
medication costs between both tapering groups. The differ-
ence in healthcare costs could change due to price variations 
of csDMARD and especially biologicals between countries. To 
investigate this, we performed a sensitivity analysis with varying 
levels of biological prices of 30%, 50% and 200% of the prices 
we currently used (online supplemental figure S2). Lowering 
biological prices was in favour of tapering the csDMARD first, 
while higher biological prices showed the opposite. However, 
biological costs are consistently higher than csDMARD costs in 
any country, meaning that the direction of the medication cost 
difference could be generalisable to other countries. For the 
current analysis, we used 2019 prices to make our results as rele-
vant as possible, since the prices for biologicals have decreased 
dramatically.
In conclusion, medication costs are lower when the TNF- 
inhibitor is tapered first, but this is counterbalanced with a 
higher loss of productivity and, therefore, cost savings are similar 
for both tapering strategies. Regardless of the WTP threshold, 
tapering the TNF- inhibitor or csDMARD first is equally cost 
effective.
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